Susceptibility to alcoholic chronic pancreatitis (ACP) could be genetically determined. Mutations in cationic trypsinogen (PRSS1), cystic fibrosis transmembrane conductance regulator (CFTR), and serine protease inhibitor, Kazal type 1 (SPINK1) genes have been variably associated with both the hereditary and the idiopathic form of chronic pancreatitis (CP). Our aim was to analyze the three genes in ACP patients. Mutational screening was performed in 45 unrelated ACP patients and 34 patients with alcoholic liver disease (ALD). No mutation of PRSS1 was found in ACP and ALD patients. Three mutations of CFTR were detected in four ACP patients with a prevalence (8.9%) not significantly different from that observed (3.0%) in ALD patients and from that expected (3.2%) in our geographical area. Neither compound heterozygotes for CFTR nor trans-heterozygotes for CFTR/SPINK1 were found. One ACP patient (2.2%) was found to carry the most common mutation (N34S) of SPINK1 compared to none of the ALD patients (P ¼ NS). In five other patients (two with ACP and three with ALD) other rare variants, including P55S, were found. In contrast with the hereditary and the idiopathic forms of CP, in which mutations of PRSS1, CFTR, and SPINK1 genes may occur, ACP is still a 'gene(s)-orphan' disease. The supposed genetic susceptibility to ACP relies on other yet unknown gene(s) which could affect the alcohol metabolism or modulate the pancreatic inflammatory response to alcohol abuse.
Introduction
Chronic pancreatitis (CP) is a potentially life-threatening disease characterized by a progressive inflammatory disorder ultimately leading to irreversible morphological changes and permanent impairment of exocrine and endocrine functions. Most patients with CP suffer from relapsing attacks of abdominal pain and are at a markedly increased risk of developing maldigestion, diabetes mellitus, and pancreatic cancer. 1 Alcoholism is the most common etiologic factor in up to 70% of patients with CP. 2 Other causes include drugs, duct-obstructing lesions, and metabolic or autoimmune disorders. In the rare form of hereditary pancreatitis (HP), at least two major mutations (R122H and N29I) in the cationic trypsinogen gene (protease, serine 1, PRSS1; OMIM: 276000) have been identified. 3, 4 In vitro biochemical studies suggest that these two mutations and additional pancreatitis-associated PRSS1 mutations 5 may inhibit autolysis of trypsin and/or enhance autoactivation of trypsinogen, resulting in a gain of trypsin. In up to 30% of patients, association with any of the aforementioned factors is lacking and the disease is classified as idiopathic (ICP). Some evidence exists that at least in a small proportion of patients with ICP, a mutation of one or both alleles of either the cystic fibrosis transmembrane conductance regulator (CFTR; OMIM: 602421) gene 6, 7 or the serine protease inhibitor, Kazal type 1 (SPINK1; OMIM: 167790) gene 8, 9 can be identified. Severe mutations in both alleles of the CFTR results in the commonly recognized cystic fibrosis (CF) clinical features of abnormal sweat chloride concentrations, pancreatic insufficiency, and progressive pulmonary disease. Among CF patients, two-thirds have a deletion of three-base pair between the nucleotides 1652 and 1655 with subsequent deletion of the phenylalanine amino acid at codon 508 (F508del), although approximately 1000 other mutations have been reported. Most CFTR mutations can be classified according to a 1 -5 severity category system based on the presumed or demonstrated molecular consequences. 10 Typical CF patients with severe pancreatic impairment tend to have two severe mutations (ie, class I, II, or III), whereas CF patients with pancreatic sufficiency from birth tend to have at least one CF 'mild allele' (ie, class IV or V).
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SPINK1 is a peptide that is synthesized by pancreatic acinar cells and colocalizes with trypsinogen in the zymogen granules. SPINK1 acts as the first line of defence against prematurely activated trypsinogen in the acinar cells by physically blocking the active site of trypsin. 8 The most known mutation (N34S) of the SPINK1 gene is relatively common (up to 4% of general population) 12 and markedly increased (up to 25%) in ICP patients. 13 Apart from N34S, other variants (like P55S) have been detected in both the general population and patients with ICP. 8 The pathogenic role of SPINK1 is still a matter of debate. Since the prevalence of ICP is low (1/16 000) 14 and the SPINK1 gene mutations are relatively common, it has been speculated by some authors that the mutated SPINK1 gene behaves as a disease modifier gene that either lowers the threshold for initiating pancreatitis or worsens the severity of pancreatitis caused by other genetic or environmental factors. 13 Other authors, however, assume that the SPINK1 gene behaves as a disease inducer gene since the N34S mutation would render SPINK1 incapable of inhibiting trypsinogen. 8 Functional investigations are currently underway in different laboratories to elucidate the exact pathophysiologic mechanism of SPINK1 mutations. The discovery of gene mutations that induce or predispose to CP led some researchers to investigate about a possible causal role of genetic factors in the occurrence and development of alcoholic chronic pancreatitis (ACP) 6,15 -18 .
Evidence for a genetic basis for ACP comes from epidemiological, laboratory, and clinical studies: only about only 5 -10% alcoholics suffer from clinically recognized CP. 19 Although a linear correlation exists between the risk of developing CP and the quantity of alcohol consumption, there is no apparent threshold of toxicity. 20 Longterm, high-dose alcohol feeding of laboratory animals fails to cause CP. 21 Finally, black patients are two to three times more likely to be hospitalized for CP than alcoholic cirrhosis when compared to white patients. 22 To date, most of the relevant studies in ACP performed mutation analysis of one single gene, that is PRSS1, or CFTR, or SPINK1. Moreover, due to differences in the selection and number of participants and the mutation screening method used, the reported mutation rates observed in one single gene varied greatly among different studies. A simultaneous analysis of all three genes in patients with ACP would provide insights into the relative contribution of each gene to the etiology of this disease. The aim of this study was to perform this kind of analysis by screening the most relevant mutations of the PRSS1, the CFTR, and the SPINK1 genes in Italian patients with ACP. As controls, we screened patients from the same geographical area who were affected by alcoholic liver disease (ALD) without a clinically recognized pancreatic disease.
Materials and methods

Patients
Patients with ACP and ALD, who were consecutively admitted to our Institution between 2000 and 2002, were enrolled for genetic analysis.
ACP was defined as a condition characterized by: (1) at least two clearly separated episodes of pancreatitis (recurring abdominal pain with a more than five-fold increase of serum lipase and amylase); (2) a reported alcohol consumption higher than 80 g per day in men and more than 60 g per day in women for more than 2 years; (3) a negative family history of pancreatitis; (4) no other obvious causes of CP, such as trauma, drugs, and obstructive biliary diseases, and (5) evidence of pancreatic calcifications on abdominal X-ray film or CT.
ALD was defined as a condition characterized by: (1) a chronic (more than 1 year) impairment of liver function tests or presence of overt clinical signs of liver cirrhosis; (2) a reported alcohol consumption higher than 80 g per day in men and more than 60 g per day in women for more than 2 years; (3) no other recognizable causes of liver diseases such as viral hepatitis, drug-induced or autoimmune hepatitis, and metabolic diseases; (4) no clinical, biochemical, or radiological signs of CP; and (5) histological signs of ALD (whenever a liver biopsy was performed to confirm the clinical suspicion).
The study protocol was approved by the local Hospital's Review Board and all patients provided informed consent.
DNA extraction
Genomic DNA was extracted from whole blood according to the established protocols using the DNA Isolation Kit for Mammalian blood (Roche Diagnostic Corporation, Indianapolis, IN, USA).
Mutation screening of the PRSS1 gene All the five exons and exon/intron junctions of the PRSS1 gene were analyzed by means of denaturing gradient gel electrophoresis (DGGE) analysis, as described by Chen et al. 9 Samples showing abnormal DGGE profiles were sequenced using the ABI Prism 377 DNA Sequencer (Applied Biosystems, Foster City, CA, USA).
Mutation screening of the CFTR gene
The 31 most frequent mutations (F508del, I507del, G551D, G542X, N1303K, 1717-1G4A, W1282X, R553X, R347P, R347H, R334W, 3849+10kb C4T, R117H, 621+1G4T, A455E, S549N, R560T, S549R, V520F, Q493X, 3849+ 4A4G, 1078delT, R1162X, 3659delC, 3905insT, Y122X, 2183delAA4G, 2789+5G4A, 1898+1G4A, 711+1G4T, and G85E) were examined with the polymerase chain reaction (PCR) followed by an oligonucleotide ligation assay (OLA, Applied Biosystems, Foster City, CA, USA) and finally a sequence-coded separation. Other seven mutations, frequently observed in Italian CF patients (Q552X; 711+5G4A; 2790-2A4G; S589N; T338I; 1898+3A4G, and 1717-8G4A), were examined by sequencing. Using both methods in the general population from the same geographical area (San Giovanni Rotondo) in which our study was performed, Gasparini et al. 23 found a carrier frequency of CFTR mutations of 3.22%. The CFTR polymorphic intron 8 polyT region was analyzed according to the method described by Chillon et al. 24 This sequence contains five, seven, or nine thymidines (5T, 7T, 9T, respectively). The 5T allele is associated with decreased splicing efficiency of intron 8, which results in the reduced levels of normal CFTR mRNA.
Mutation screening of the SPINK1 gene Molecular study of the SPINK1 gene was performed by PCR amplification and sequencing of the entire coding region and the intron/exon junctions, as described by Witt et al.
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All mutations were confirmed by means of RFLP (restriction endonuclease: TaaI, MBI Fermentas, Germany) or PCR with confronting two pair primer (PCR-CTPP) 25 assays. 
Statistical analysis
Results
Patients
A total of 45 unrelated Caucasian patients (44 males; mean age: 38 years) with ACP and 34 patients (28 males; mean age: 44 years) with ALD were studied. We did not find any significant difference between the two groups of patients as far as alcohol consumption (160740 vs 140740 g/day in men with ACP and ALD, respectively) and smoking habits (26 (57.8%) ACP and 19 (55.9%) ALD patients had a current or past smoking history) was considered. Furthermore, no specific association was observed between any demographic or clinical subjects' characteristics and gene mutations (Table 1) .
Mutation analysis of the PRSS1 gene
Mutation analysis of PRSS1 was performed in all patients with ACP and ALD. No mutation of the gene was found in both patient groups (Tables 2 and 3 ).
Mutation analysis of the CFTR gene
Mutation analysis of CFTR was performed in all ACP patients and in all ALD patients except one due to insufficient DNA sample. In four ACP patients, three mutations were detected in heterozygous state (Table 2) with a prevalence rate of 8.88%. This prevalence was not significantly different from the expected prevalence of 3.22% (P ¼ 0.64) in our geographical area. No patient with ACP carrying CFTR mutations had the 5T allele (Table 2) . A single mutation in the heterozygous state was detected in one ALD patient with a prevalence rate (3.03%) similar to that expected in the general population. This patient also had a 5T allele in the heterozygous state (Table 3) . Neither compound heterozygotes for CFTR nor trans-heterozygotes for CFTR/SPINK1 genes were found in our study population (Tables 2 and 3 ).
Mutation analysis of the SPINK1 gene Mutation analysis identified the most known mutation (N34S) of SPINK1 in one ACP patient (2.2%). compared to none of the ALD patients (P ¼ NS). P55S (a likely CFTR, PRSS1 and SPINK1 genes in alcoholic CP F Perri et al polymorphism) and two other rare variants (IVS2-23A4T and M1T) were found in five patients (two with ACP and three with ALD) (Tables 2 and 3 ).
Discussion
The pathogenesis of ACP is still an unresolved problem. Several different theories have been made such as duct obstruction by protein plugs, direct toxicity of ethanol, and oxidative stress. 26 Very recently, fatty acid ethyl esters, which are by-products of the nonoxidative metabolism of ethanol in the pancreas, have been proposed as possible etiologic factors. 27 However, none of these mechanisms has yet found a solid experimental support to gain wide acceptance. As already mentioned, evidence for a genetic basis for ACP comes from epidemiological, laboratory, and clinical studies. 19 -22 Although susceptibility to alcoholic pancreatic damage could be inherited, until now no clear association between any gene mutation(s) and occurrence of ACP in alcoholics has been found. In particular, during the last 6 years, three single genes (PRSS1, CFTR, and SPINK1) have been investigated in patients with ACP. Screening for mutations of PRSS1 has been always negative 16, 17, 28 confirming that PRSS1 mutations have no role in determining or predisposing to pancreatic damage by alcohol. Mutations of CFTR (including mutations in the noncoding sequence of thymidines in intron 8) have been detected in patients with ACP, but their prevalence is similar to that expected in the general population. 6, 15, 17, 29 Finally, the most common mutation (N34S) in SPINK1 has been found more frequently associated in patients with ACP than in healthy controls or in patients with alcoholism but without CP. 18, 30 However, this finding has not been confirmed in any another study.
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In the present study, we performed a simultaneous analysis of all the three genes in patients with ACP. Our working hypothesis was that the pancreatic damage due to high alcohol intake could be due to either an abnormal allele in one of the three genes or a combination of multiple mutations occurring in the two alleles of the same gene (compound heterozygote) or different genes (trans- Table 2 Sequence variations identified in the PRSS1, CFTR, and SPINK1 genes in 45 ACP patients Table 2 .
CFTR, PRSS1 and SPINK1 genes in alcoholic CP F Perri et al heterozygote). This hypothesis has already been successfully tested in both ICP and tropical calcific pancreatitis (TCP). The latter is an idiopathic, juvenile, nonalcoholic form of CP widely prevalent in several tropical countries. By simultaneously analyzing 39 ICP subjects for common mutations of CFTR, SPINK1, and PRSS1, Noone et al.
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found that about 60% of their patients had at least one mutation in either CFTR or SPINK1, or both. Interestingly, the risk of pancreatitis was increased approximately fivefold by having one CFTR mutation, 20-fold by having SPINK1 N34S mutation, 40-fold by having two CFTR mutations (compound heterozygotes), and 900-fold by having N34S and two CFTR mutations. By using a similar approach, Audrézet et al. 32 found that at least 30% of 39
French patients with ICP carried at least one abnormal allele in one of the three genes, with a compound heterozygote state for CFTR in four patients and a transheterozygote state for SPINK1/CFTR genes in other three patients. Very recently, Chandak et al. 33 found that about half of the patients suffering from TCP carried a mutation (predominantly the N34S) in the SPINK1 and no mutation in the PRSS1 gene. These findings are consistent with the hypothesis that all these genes may be involved in the pathogenesis and phenotypic variability of both ICP and TCP. Unfortunately, our findings in ACP were disappointing since only seven patients were found to carry at least one mutation in the heterozygous state in either CFTR or SPINK1. Moreover, no compound heterozygote or transheterozygote was observed. The prevalence of these mutations was not significantly different between patients with ACP and those with ALD. Three patients also had the 5T allele in intron 8, but none of them showed a concurrent mutation in CFTR. Mutational screening of PRSS1 and SPINK1 genes was performed by techniques similar to those adopted by other research groups. Consequently, methodological problems are not likely to be involved in our negative findings. In contrast, we did not perform a complete analysis of the CFTR gene, which consists of 24 exons encoding 1480 amino acids, but we investigated only a selected subset of the most common CFTR mutations in CF. Therefore, minor ('mild') mutations in the CFTR gene cannot be completely excluded in our patients since the entire gene would have been sequenced. It would be tempting to speculate that atypical CFTR alleles are likely to be associated with a higher residual CFTR function, which by itself is unable to induce pancreatic damage but in combination with a heavy alcohol intake could be sufficient to determine pancreatitis. Nevertheless, the functional consequence of minor variants is still unknown especially when no concurrent major mutation in the CFTR gene is detected in the same patient. Moreover, one would speculate that an alcoholic drinker who simultaneously carries a major mutation of the CFTR gene in one allele and a minor mutation of the same gene in the other allele is likely to be more affected by an atypical form of CF with CP than ACP. In the present study, the prevalence of mutations of CFTR in ACP patients was similar to that observed in ALD and expected in normal population from the same geographical area.
Finally, two potential drawbacks of the present work should be pointed out. The lack of a significant difference in the prevalence of gene mutations between ACP and ALD patients could be affected by a beta error due to the small sample size. The use of ALD patients as pathological controls does not afford us to extrapolate the conclusions of this study to a healthy population. Future studies should be designed with large sample sizes including healthy controls in order to avoid these potential shortcomings.
In summary, this study shows that mutations in PRSS1, CFTR, and SPINK1 genes are occasionally found in patients with ACP, but their prevalence is not significantly increased in comparison with alcoholics who develop ALD without clinical, biochemical, or radiological signs of CP. In striking contrast with the HP and the so-called ICP in which mutations of these genes occur at variable frequency, ACP is still a 'gene(s)-orphan' disease. The supposed genetic susceptibility to pancreatic alcohol damage should be searched in other yet unknown genes that could affect the alcohol metabolism or modulate the pancreatic inflammatory response to alcohol abuse.
